Chemopreventive Effects of Epigallocatechin Gallate (EGCG) in Colorectal Cancer (CRC) Patients

Inclusion Criteria: * Cytologically or histologically confirmed of primary colon or rectal adenocarcinoma with resectable cancer, who have not received any treatments for cancer. * Age 18 years and above * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 * The patient is a candidate for surgical resection, with no planned neoadjuvant chemotherapy, and there is a planned surgery for the primary colorectal cancer cancer or the patient had recent resection of the primary colorectal cancer. . * For women who are not postmenopausal (12 months of amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to use two adequate methods of contraception. For men: agreement to use a barrier method of contraception during the treatment period * Hematologic, Biochemical, and Organ Function within 7 days prior to Cycle 1 Day 1: Granulocyte count \> 1000/mm3, Platelet count \> 50,000/ mm3, Hemoglobin \> 7 g/dL; Total bilirubin \< 1.5xULN; Albumin \> 2.8g/dl; aspartate aminotransferase (AST) (SGOT) and alanine aminotransferase (ALT) (SGPT) \</=2.5 x upper limit of normal (ULN); Serum creatinine\< 2 x ULN Exclusion Criteria: * Patients receiving prior chemotherapy or chemoradiation for colorectal cancer (ie, neoadjuvant chemoradiation for stage II or III rectal cancer). * Known diagnosis of stage III colon or rectal cancer will be excluded from the study. * Patients with metastatic disease. * Patients may not be receiving any other investigational age…